Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01859793 · ClinicalTrials.gov registry record · Phase 4
Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
A Phase 4 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
NCT01859793 is a Phase 4 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 38 participants.
The verdict
NCT01859793, a Phase 4 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
Study Summary
The study is being performed to determine whether sitagliptin, a dipeptidyl peptidase-4 inhibitor, both acutely and chronically improves blood vessel function. Patients with type 2 diabetes who are on metformin will be enrolled in this study for up to 22 weeks in this double blinded cross over study where they will receive a sitagliptin pill once a day for 8 weeks and during a separate 8 weeks receive a matching placebo pill. The treatment periods are divided by a 4 week period. Blood vessel function will be measured by ultrasound before and after a single dose of sitagliptin and placebo, as well as after 8 weeks of treatment with each. Blood will also be taken to measure blood markers of inflammation at each time the ultrasounds are performed.
Interventions
- DRUG Placebo
- DRUG sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01859793
The ClinicalTrials.gov registry entry for NCT01859793 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01859793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01859793 about?
NCT01859793 is a clinical study titled "Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy". The study is being performed to determine whether sitagliptin, a dipeptidyl peptidase-4 inhibitor, both acutely and chronically improves blood vessel function. Patients with type 2 diabetes who are on metformin will be enrolled in this study for up to 22 weeks in this double blinded cross over study...
What is the current status of trial NCT01859793?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2013-06. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01859793?
The interventions under investigation include: Placebo (DRUG), sitagliptin (DRUG).
Who is sponsoring clinical trial NCT01859793?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.